We chose Sitagliptin because it has a high specificity against DPP4 and was the first DPP4 inhibitor approved by the Food and Drug Administration (FDA) for use in type 2 diabetes in 2006 with successful use in patients since. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.